About Us

Who are we?

SELECTBIO provides focused market reports, custom consultancy, training courses and conferences to the biomedical marketplace.

We also offer a managed events service, so if you are planning your own conference and need some assistance please click here.

SELECTBIO was established in 1999 to provide scientific consultancy services to the biomedical industry.

From organising just three conferences in 2004, SELECTBIO now organise around 70 conferences, training courses and tutorials every year, across Europe, the USA and Asia.

Select Bio Building

Queens Award 2010

In 2010 SELECTBIO won the coveted Queen’s Award for Enterprise, acknowledging our eleven-fold growth in overseas sales over six years. This is a tremendous boost for our company as we continue to seek new markets and opportunities for further expansion over the coming years.

Conference News

The ethics around biobanking – an interview with Zubin Master
This week’s blog focusses on the ethical issues surrounding biobanking, based on a recent interview we conducted with Zubin Master. Dr Master, Assistant Professor at the Alden March Bioethics Institute of Albany Medical College, will be discussing this topic in detail at ELA 2013 as part of his presentation, “Biobanks: Consent, Consensus & Public Trust.”

Standards Make High-Content Screening Data More Powerful.....An Interview with Dr Stephan Schürer
Dr Stephan Schürer from the University of Miami speaks about the goals of the BioAssay Ontology Project to enable standardized description, integration and meta-analysis of assay and screening results - http://bit.ly/15HpwvN Dr Schürer will be discussing this topic in more detail at ELA 2013 as part of the Drug Discovery Automation track - http://bit.ly/16jbuPq

5 Reasons Not to Miss ELA 2013
We understand that staying up-to-date on the latest technologies boosting efficiency and effectiveness in the lab can be challenging. That’s exactly why we created ELA. Our latest blog entry - http://bit.ly/15HpwvN - highlights five key reasons not to miss this year’s event, all based on feedback we’ve received from past attendees.

The future of HCA using primary cells and 3D culture
This week’s ELA blog - http://bit.ly/15HpwvN -discusses the impact of process optimisation on cell based assays, with particular reference to High Content Analysis (HCA). To give us the inside scoop, we chatted with Dr Anthony Davies, Director of the High Content Research Facility at the Irish National Center for High Content Screening and Analysis (INCHSA) at Trinity College, Dublin, about the impact automation has had on the workflow at INCHSA. Dr Davies will also be sharing his expertise at E

'Illuminating Cellular Pathways through Combining High Content Assays with the BDA Method'
Keynote talk to be delivered by Dr Hakim Djaballah, Director, Memorial Sloan Kettering Cancer Center 'Illuminating Cellular Pathways through Combining High Content Assays with the BDA Method: Too Much Hay and Very Few Needles in Random RNAi Screening Stacks' at the DDA: High-content Screening & Cell Based Assays conference track at ELA. For the full agenda, please view: http://bit.ly/YSUu0P

Post Event Lab Tour
On November 14th there will be a post event lab tour, free for Lab-on-a-Chip Asia conference attendees. This will include visits to Singapore Institute of Manufacturing Technology, Nanyang Technological University, and National University of Singapore.